Abstract
The introduction of TATs is challenging for stakeholders involved in cancer care; their approval in several markets and initiatives to support their uptake are changing healthcare systems’ readiness for precision oncology. We aimed to measure healthcare systems’ readiness for TATs over time and in different countries.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
